IN2014KN01714A - - Google Patents

Info

Publication number
IN2014KN01714A
IN2014KN01714A IN1714KON2014A IN2014KN01714A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A IN 1714KON2014 A IN1714KON2014 A IN 1714KON2014A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A
Authority
IN
India
Prior art keywords
antibody
cancer
amino acid
acid sequence
seq
Prior art date
Application number
Other languages
English (en)
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of IN2014KN01714A publication Critical patent/IN2014KN01714A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
IN1714KON2014 2012-02-21 2013-02-21 IN2014KN01714A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035342 2012-02-21
PCT/JP2013/054312 WO2013125630A1 (ja) 2012-02-21 2013-02-21 癌の治療及び/又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
IN2014KN01714A true IN2014KN01714A (pt) 2015-10-23

Family

ID=49005808

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1714KON2014 IN2014KN01714A (pt) 2012-02-21 2013-02-21

Country Status (17)

Country Link
US (1) US9260513B2 (pt)
EP (1) EP2818481B1 (pt)
JP (1) JP6187257B2 (pt)
KR (1) KR102005308B1 (pt)
CN (1) CN104114581B (pt)
AU (1) AU2013223137B2 (pt)
BR (1) BR112014021099A2 (pt)
CA (1) CA2864999C (pt)
DK (1) DK2818481T3 (pt)
ES (1) ES2749672T3 (pt)
HU (1) HUE046788T2 (pt)
IN (1) IN2014KN01714A (pt)
MX (1) MX363136B (pt)
PL (1) PL2818481T3 (pt)
PT (1) PT2818481T (pt)
RU (1) RU2639522C2 (pt)
WO (1) WO2013125630A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2325648E (pt) 2008-08-05 2014-06-24 Toray Industries Método para detetar cancro
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
PT2532743E (pt) * 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
AU2012290949B2 (en) * 2011-08-04 2017-03-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
MX349907B (es) * 2011-08-04 2017-08-18 Toray Industries Metodo para detectar cancer pancreatico.
PL2818483T3 (pl) 2012-02-21 2018-01-31 Toray Industries Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
JP6107654B2 (ja) * 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び/又は予防用医薬組成物
PL2832366T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego
KR102056137B1 (ko) 2012-07-19 2019-12-16 도레이 카부시키가이샤 암의 검출 방법
PT2876446T (pt) 2012-07-19 2019-03-25 Toray Industries Método para deteção de cancro
JP6447130B2 (ja) 2013-08-09 2019-01-09 東レ株式会社 癌の治療及び/又は予防用医薬組成物
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
KR20190075921A (ko) 2016-10-28 2019-07-01 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
JP7342701B2 (ja) * 2018-03-30 2023-09-12 東レ株式会社 癌の治療及び/又は予防用医薬組成物
KR20220004634A (ko) 2019-03-15 2022-01-11 볼트 바이오테라퓨틱스 인코퍼레이티드 Her2를 표적으로 하는 면역접합체
BR112021025034A2 (pt) 2019-06-13 2022-04-26 Bolt Biotherapeutics Inc Imunoconjugado, composto aminobenzazepina-ligante, composição farmacêutica, métodos para tratar câncer e para preparar um imunoconjugado e uso de um imunoconjugado
MX2022003740A (es) 2019-09-30 2022-05-02 Bolt Biotherapeutics Inc Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos.
WO2021081407A1 (en) 2019-10-25 2021-04-29 Bolt Biotherapeutics, Inc. Thienoazepine immunoconjugates, and uses thereof
JPWO2021182570A1 (pt) 2020-03-12 2021-09-16
BR112022018157A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
JPWO2021182574A1 (pt) * 2020-03-12 2021-09-16
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20230140155A1 (en) 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JP2023524271A (ja) 2020-05-08 2023-06-09 ボルト バイオセラピューティクス、インコーポレーテッド エラスターゼ-基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用
US20230263903A1 (en) 2020-08-13 2023-08-24 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
WO2022270524A1 (ja) 2021-06-23 2022-12-29 東レ株式会社 癌の治療及び/又は予防のための医薬品
JPWO2022270523A1 (pt) 2021-06-23 2022-12-29
AU2022319362A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2023008461A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び/又は予防のための医薬品
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
KR20240051956A (ko) 2021-09-03 2024-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2023076599A1 (en) 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
US6677436B1 (en) 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
EP1187915A2 (en) 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1224285A4 (en) 1999-10-29 2004-12-08 Human Genome Sciences Inc 27 HUMAN SECRETED PROTEINS
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2001261007A1 (en) 2000-03-29 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2508763C (en) 2001-05-11 2012-01-24 Kirin Beer Kabushiki Kaisha Human antibody producing mouse and method for producing human antibody using the same
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1575480A4 (en) 2002-02-22 2008-08-06 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
CA2504144A1 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro7
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
WO2004097051A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
EP1711525A2 (en) 2004-01-26 2006-10-18 Debiovision Inc. Neoplasm-specific polypeptides and their uses
CA2560305C (en) 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
PL1730191T3 (pl) 2004-03-30 2011-12-30 Glaxo Group Ltd Immunoglobuliny wiążące hosm
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
US7858324B2 (en) 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
KR101310000B1 (ko) 2005-03-11 2013-09-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US8211634B2 (en) 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008031041A2 (en) 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
NZ602675A (en) 2008-03-18 2014-03-28 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
PT2325648E (pt) 2008-08-05 2014-06-24 Toray Industries Método para detetar cancro
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
BRPI0912462B1 (pt) 2008-08-05 2022-03-22 Toray Industries, Inc Uso de um agente indutor de imunidade, uso de um polipeptídeo e uso de um vetor recombinante
BR112012003686B1 (pt) 2009-08-19 2021-09-21 Merck Patent Gmbh Anticorpos monoclonais, seu uso para detecção de complexos de integrina em material ffpe, e polinucleotídeo
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга
HUE040012T2 (hu) * 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
PT2532743E (pt) 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
US8911740B2 (en) 2010-02-04 2014-12-16 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PL2532365T3 (pl) 2010-02-04 2016-12-30 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
RU2567657C2 (ru) 2010-02-04 2015-11-10 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
HUE030742T2 (en) 2010-02-04 2017-06-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
KR101271964B1 (ko) 2010-07-08 2013-06-07 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
US10533050B2 (en) 2010-07-26 2020-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for liver cancer therapy
JP5545105B2 (ja) 2010-08-04 2014-07-09 株式会社ジェイテクト トロイダル型無段変速機のディスクの研磨方法およびトロイダル無段変速機のディスクの研磨装置
AU2012290949B2 (en) 2011-08-04 2017-03-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
MX349907B (es) * 2011-08-04 2017-08-18 Toray Industries Metodo para detectar cancer pancreatico.
CN103717740B (zh) 2011-08-04 2015-10-21 东丽株式会社 癌的治疗和/或预防用药物组合物
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び/又は予防用医薬組成物
PL2832366T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego

Also Published As

Publication number Publication date
RU2014138039A (ru) 2016-04-10
US20150044221A1 (en) 2015-02-12
HUE046788T2 (hu) 2020-03-30
WO2013125630A1 (ja) 2013-08-29
CA2864999A1 (en) 2013-08-29
JPWO2013125630A1 (ja) 2015-07-30
BR112014021099A2 (pt) 2020-12-01
PT2818481T (pt) 2019-10-25
AU2013223137A1 (en) 2014-09-11
CN104114581B (zh) 2018-11-30
PL2818481T3 (pl) 2020-02-28
RU2639522C2 (ru) 2017-12-21
CA2864999C (en) 2020-06-30
EP2818481A4 (en) 2015-10-07
AU2013223137B2 (en) 2017-10-19
KR20140130670A (ko) 2014-11-11
JP6187257B2 (ja) 2017-08-30
CN104114581A (zh) 2014-10-22
MX2014009747A (es) 2014-11-14
MX363136B (es) 2019-03-12
EP2818481A1 (en) 2014-12-31
US9260513B2 (en) 2016-02-16
DK2818481T3 (da) 2019-10-14
KR102005308B1 (ko) 2019-07-30
ES2749672T3 (es) 2020-03-23
EP2818481B1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
IN2014KN01713A (pt)
IN2014KN01714A (pt)
IN2014KN01716A (pt)
IN2014KN01715A (pt)
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
MX2016001640A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
MX371442B (es) VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
MY167232A (en) Polypeptides binding to human complement c5
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
IN2014DN09963A (pt)
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.
WO2014039074A3 (en) Therapeutic compositions and related methods
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same